![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication July 23, 2003.
Revised September 22, 2003.
Accepted for publication October 23, 2003.
Calcimimetic compounds, which activate the parathyroid cell Ca2+ receptor (CaR) and inhibit parathyroid hormone (PTH) secretion, are under experimental study as a treatment for hyperparathyroidism (HPT). This report describes the salient pharmacodynamic properties, using several test systems, of a new calcimimetic compound, cinacalcet HCl. Cinacalcet HCl increased the concentration of cytoplasmic Ca2+ ([Ca2+]i) in HEK 293 cells expressing the human parathyroid CaR. Cinacalcet HCl (EC50 = 51 nM) in the presence of 0.5 mM extracellular Ca2+ elicited increases in [Ca2+]i) in a dose and calcium dependent manner. Similarly, in the presence of 0.5 mM extracellular Ca2+, cinacalcet HCl (IC50 = 28 nM) produced a concentration-dependent decrease in PTH secretion from cultured bovine parathyroid cells. Using rat medullary thyroid carcinoma (MTC) 6-23 cells that express the CaR, cinacalcet HCl (IC50 = 34 nM) produced a concentration-dependent increase in calcitonin secretion. In vivo studies in rats demonstrated cinacalcet HCl is orally bioavailable and displays approximately linear pharmacokinetics over the dose range of 1 to 36 mg/kg. Furthermore, this compound suppressed serum PTH and blood-ionized Ca2+ levels and increased serum calcitonin levels in a dose-dependent fashion. Cinacalcet HCl was about 30-fold more potent at lowering serum levels of PTH than it was at increasing serum calcitonin levels. The S-enantiomer of cinacalcet (S-AMG 073) was at least 75-fold less active in these assay systems. The present findings provide compelling evidence that cinacalcet HCl is a potent and stereoselective activator of the parathyroid CaR and, as such, might be beneficial in the treatment of hyperparathyroidism.
Key words:
calcimimetics, calcium, calcium sensing receptor, cinacalcet, hyperparathyroidism, parathyroid hormone
This article has been cited by other articles:
|
|
 |
|
  K. Nakagawa, E. C. Perez, J. Oh, F. Santos, A. Geldyyev, M.-L. Gross, F. Schaefer, and C. P. Schmitt Cinacalcet does not affect longitudinal growth but increases body weight gain in experimental uraemia Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2761 - 2767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. M. de Francisco, M. Izquierdo, J. Cunningham, C. Pinera, R. Palomar, G. F. Fresnedo, J. A. Amado, M. G. Unzueta, and M. Arias Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2895 - 2901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Block, S. Zeig, J. Sugihara, G. M. Chertow, E. M. Chi, S. A. Turner, D. A. Bushinsky, and for the TARGET Investigators Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism Nephrol. Dial. Transplant., July 1, 2008; 23(7): 2311 - 2318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. F. Nemeth Anabolic Therapy for Osteoporosis: Calcilytics IBMS BoneKEy, June 1, 2008; 5(6): 196 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fukagawa, S. Yumita, T. Akizawa, E. Uchida, Y. Tsukamoto, M. Iwasaki, S. Koshikawa, and KRN1493 study group Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favourable control of the serum phosphorus and calcium levels in Japanese dialysis patients Nephrol. Dial. Transplant., January 1, 2008; 23(1): 328 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Carrera Foreword NDT Plus, January 1, 2008; 1(suppl_1): i1 - i1. [Full Text] [PDF]
|
|
|
|
|
|
D. Riccardi and D. Martin The Role of the Calcium-Sensing Receptor in the Pathophysiology of Secondary Hyperparathyroidism NDT Plus, January 1, 2008; 1(suppl_1): i7 - i11. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Silverberg, M. R. Rubin, C. Faiman, M. Peacock, D. M. Shoback, R. C. Smallridge, L. E. Schwanauer, K. A. Olson, P. Klassen, and J. P. Bilezikian Cinacalcet Hydrochloride Reduces the Serum Calcium Concentration in Inoperable Parathyroid Carcinoma J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3803 - 3808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Ortiz-Capisano, P. A. Ortiz, J. L. Garvin, P. Harding, and W. H. Beierwaltes Expression and Function of the Calcium-Sensing Receptor in Juxtaglomerular Cells Hypertension, October 1, 2007; 50(4): 737 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Drueke, D. Martin, and M. Rodriguez Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1828 - 1839. [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Rodriguez, Y. Almaden, S. Canadillas, A. Canalejo, E. Siendones, I. Lopez, E. Aguilera-Tejero, D. Martin, and M. Rodriguez The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands Am J Physiol Renal Physiol, May 1, 2007; 292(5): F1390 - F1395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Robinson, J. J. Augustine, and N. J. Korman Cinacalcet for the Treatment of Calciphylaxis Arch Dermatol, February 1, 2007; 143(2): 152 - 154. [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Davies, C. E. Gibbons, T. Vizard, and D. T. Ward Ca2+-sensing receptor induces Rho kinase-mediated actin stress fiber assembly and altered cell morphology, but not in response to aromatic amino acids Am J Physiol Cell Physiol, June 1, 2006; 290(6): C1543 - C1551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Chertow, S. Blumenthal, S. Turner, M. Roppolo, L. Stern, E. M. Chi, J. Reed, and on behalf of the CONTROL Investigators Cinacalcet Hydrochloride (Sensipar) in Hemodialysis Patients on Active Vitamin D Derivatives with Controlled PTH and Elevated Calcium x Phosphate Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 305 - 312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kawata, Y. Imanishi, K. Kobayashi, T. Kenko, M. Wada, E. Ishimura, T. Miki, N. Nagano, M. Inaba, A. Arnold, et al. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism Eur. J. Endocrinol., October 1, 2005; 153(4): 587 - 594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Henley, M. Colloton, R. C. Cattley, E. Shatzen, D. A. Towler, D. Lacey, and D. Martin 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar(R)/Mimpara(R)) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism Nephrol. Dial. Transplant., July 1, 2005; 20(7): 1370 - 1377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Lindberg, B. Culleton, G. Wong, M. F. Borah, R. V. Clark, W. B. Shapiro, S. D. Roger, F. E. Husserl, P. S. Klassen, M. D. Guo, et al. Cinacalcet HCl, an Oral Calcimimetic Agent for the Treatment of Secondary Hyperparathyroidism in Hemodialysis and Peritoneal Dialysis: A Randomized, Double-Blind, Multicenter Study J. Am. Soc. Nephrol., March 1, 2005; 16(3): 800 - 807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rodriguez, E. Nemeth, and D. Martin The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism Am J Physiol Renal Physiol, February 1, 2005; 288(2): F253 - F264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S Joy, A. V Kshirsagar, and N. Franceschini Calcimimetics and the Treatment of Primary and Secondary Hyperparathyroidism Ann. Pharmacother., November 1, 2004; 38(11): 1871 - 1880. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
